Rimidi and Companion Medical announced a first-of-its-kind partnership to enhance data visualization for clinicians treating high-risk patients with diabetes who are on insulin therapy. The collaboration integrates Companion Medical’s connected device, InPen(TM), the first and only FDA-cleared, smart insulin pen paired with an integrated diabetes management app, into Rimidi’s platform by pushing insulin dosing data from the InPen through the cloud.
Integration Benefits
This partnership reduces the burden in new technology adoption for healthcare systems and also enables innovation in population health and care delivery models, resulting in improved outcomes at a decreased cost of care. Working within the electronic health record (EHR), Rimidi’s software enables personalized, virtual management of individuals with cardiometabolic conditions by combining connected devices with relevant clinical data.
Desert Oasis Healthcare (DOHC) Joint Project
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Rimidi and Companion Medical has initiated their partnership with a project at Desert Oasis Healthcare (DOHC) in Southern California, an innovative practice that is part of the Heritage Provider Network, and intend to offer this solution to other national healthcare systems.
“We have used Rimidi’s software with connected glucometers for five years with very positive effects on diabetes outcomes, showing improvements in both [hemoglobin] A1C and ‘bad’ cholesterol,” said Lindsey Valenzuela, PharmD, APh, BCACP, Administrator of Population Health and Prescription Management (PHARxM) at DOHC. “The addition of insulin dosing data will be significant. It will meaningfully accelerate the trial and error process of identifying the optimal dose for each patient while reducing costs.”
Date: June 11, 2019
Source: HIT Consultant
